The Motley Fool··Eric VolkmanNektar Therapeutics Surges 18% on Positive Alopecia Drug Trial Results
Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.
NKTRclinical trial resultsbiotech stock